Cogstate Limited revised earnings guidance for the fiscal year ending 30 June 2023. For the year, revenue expected to be approximately 6% to 9% below fiscal year 2022; EBIT is expected to be in the range of 6% to 8% of revenue (4 November 2022 guidance of 20% to 24%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.395 AUD | +1.82% | +7.31% | -3.46% |
Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
Feb. 22 | Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.46% | 153M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- CGS Stock
- News Cogstate Limited
- Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023